Last edition
News about "Chugai Pharma"
Chugai Pharma's Avastin Secures Approval in Japan for Additional Indication
Chugai Pharma’s Avastin has received approval in Japan for an additional indication, becoming the world’s first therapeutic option for neurofibromatosis type 2. The approval is supported by positive phase 2 clinical study results.
Chugai Pharma | 22/06/2026 | By News Bureau
Chugai Pharma concludes licence agreement with Roche for CT-388
Chugai Pharmaceutical has signed a licensing deal with F. Hoffmann-La Roche for CT-388, a long-acting GLP-1/GIP receptor agonist for obesity and type-II diabetes, granting Chugai exclusive development and marketing rights in Japan.
Chugai Pharma | 11/10/2025 | By Dineshwori | 671
Chugai Pharma obtains regulatory approval for anti-SARS-CoV-2 monoclonal antibody Ronapreve
Chugai Pharmaceutical has obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for the anti-SARS-CoV-2 monoclonal antibody Ronapreve for Intravenous Infusion Set 300 and Set 1332 for the indication of SARS-CoV-2 infection
Chugai Pharma | 21/07/2021 | By Darshana | 227
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy